✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
TVB-2640 is an investigational drug.
There have been 10 clinical trials for TVB-2640. The most recent clinical trial was a Phase 2 trial, which was initiated on November 18th 2021.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Liver Diseases, and Fatty Liver. The leading clinical trial sponsors are Sagimet Biosciences Inc., Ascletis Pharmaceuticals Co., Ltd., and 3V Biosciences, Inc.
There is one US patent protecting this investigational drug and one hundred and eight international patents.
Recent Clinical Trials for TVB-2640
|A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-TVB-2640 Following a Single Oral Dose in Healthy Male Subjects||Sagimet Biosciences Inc.||Phase 1|
|Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM||Ascletis Pharmaceuticals Co., Ltd.||Phase 3|
|Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)||Sagimet Biosciences Inc.||Phase 2|
Top disease conditions for TVB-2640
Top clinical trial sponsors for TVB-2640
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|TVB-2640||See Plans and Pricing||Heterocyclic modulators of lipid synthesis||3-V Biosciences, Inc. (Menlo Park, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|TVB-2640||Canada||CA2979696||2035-03-19||See Plans and Pricing|
|TVB-2640||China||CN107428728||2035-03-19||See Plans and Pricing|
|TVB-2640||European Patent Office||EP3277675||2035-03-19||See Plans and Pricing|
|TVB-2640||Spain||ES2910049||2035-03-19||See Plans and Pricing|
|TVB-2640||Japan||JP2018508547||2035-03-19||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|